Study S003283

Pharmacokinetics and Safety of HR17031 Injection in Subjects With Mild and Moderate Liver Impairment and Normal Liver Function.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05151705
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: UNKNOWN
Enrollment: 24
Start: 2021-12-20
Primary completion: 2022-06-15
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Conditions: Improved Glycemic Control in Patients With Type 2 Diabetes
Interventions: DRUG:HR17031 injection
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Pharmacokinetics parameters of INS068 and SHR20004: Cmax [Based on pre-dose, 2-96 hours post-dose sampling times]
Pharmacokinetics parameters of INS068 and SHR20004: AUC0-t [Based on pre-dose, 2-96 hours post-dose sampling times]
Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf [Based on pre-dose, 2-96 hours post-dose sampling times]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.